New ADHD drug centanafadine gains US approval with multitarget mechanism

Otsuka’s novel medicine, centanafadine, has been approved in the US for treating ADHD in adults and children, marking a potential breakthrough with its unique action on three key brain chemicals, though regulatory status in Australia remains pending.

A new ADHD medicine, centanafadine, has moved into the spotlight after gaining US approval for adults and children aged six and older, with the brand name Simtriyo. Otsuka Pharmaceutical said the drug was cleared by the US Food and Drug Administration on 24 July 2026, while the FDA’s own novel-drug register lists Simtriyo as an ADHD treatment approved on that date. It is not yet approved in Australia, and the Therapeutic Goods Administration has not listed it for use there. (otsuka.co.jp)

What makes centanafadine notable is its mechanism. The drug is the first approved medicine of its kind to act on three key brain chemicals at once: norepinephrine, dopamine and serotonin. Otsuka describes it as a norepinephrine, dopamine and serotonin reuptake inhibitor, meaning it helps keep those neurotransmitters available for longer in brain pathways linked to attention and behavioural control. That sets it apart from many current ADHD medicines, which generally focus on dopamine and norepinephrine rather than all three. (otsuka.co.jp)

Researchers have been studying centanafadine for some time. The FDA label says its paediatric approval was based on two short-term placebo-controlled studies, while adult data came from larger phase 3 trials. A systematic review and meta-analysis in PubMed Central reported that five randomised controlled trials involving 1,968 participants found the drug reduced ADHD symptoms more than placebo, although the reviewers said longer-term follow-up is still needed. Otsuka also said earlier this year that phase 3 analyses suggested benefits in adults with ADHD and anxiety, with improvements appearing as early as week one in a separate study. (accessdata.fda.gov)

As with other ADHD treatments, side effects remain an important consideration. The most commonly reported problems include reduced appetite, headache, dry mouth and insomnia. MedlinePlus, which provides patient drug information, also notes a warning about suicidal thoughts and behaviour in young people, and advises close monitoring during treatment. Otsuka’s approval announcement said the medicine was generally well tolerated, but regulators and clinicians are expected to keep watching real-world use closely as more patients take it. (accessdata.fda.gov)

For Australian families, the immediate impact is limited because centanafadine has yet to clear local regulatory hurdles. If it does eventually gain approval, it could widen the options for children and adults who do not respond well to existing medicines or who struggle with side effects. Early company data have also prompted interest in whether the drug may help people with ADHD and co-existing anxiety or depression, but that remains an open question until fuller trial results are published. (otsuka.co.jp)